A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
Phase of Trial: Phase III
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 12 Dec 2018 Planned End Date changed from 15 Apr 2020 to 13 Aug 2020.
- 28 Feb 2018 Planned End Date changed from 13 Nov 2019 to 15 Apr 2020.
- 28 Dec 2017 Status changed from not yet recruiting to recruiting.